Literature DB >> 24920662

Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis.

Yang Zhou1, Hong Peng2, Huanxing Sun1, Xueyan Peng1, Chuyan Tang1, Ye Gan1, Xiaosong Chen1, Aditi Mathur1, Buqu Hu1, Martin D Slade1, Ruth R Montgomery3, Albert C Shaw3, Robert J Homer4, Eric S White5, Chang-Min Lee1, Meagan W Moore1, Mridu Gulati1, Chun Geun Lee1, Jack A Elias6, Erica L Herzog1.   

Abstract

Epithelial injury, alternative macrophage accumulation, and fibroproliferation coexist in the lungs of patients with idiopathic pulmonary fibrosis (IPF). Chitinase 3-like 1 (CHI3L1) is a prototypic chitinase-like protein that has been retained over species and evolutionary time. However, the regulation of CHI3L1 in IPF and its ability to regulate injury and/or fibroproliferative repair have not been fully defined. We demonstrated that CHI3L1 levels were elevated in patients with IPF. High levels of CHI3L1 are associated with progression--as defined by lung transplantation or death--and with scavenger receptor-expressing circulating monocytes in an ambulatory IPF population. In preterminal acute exacerbations of IPF, CHI3L1 levels were reduced and associated with increased levels of apoptosis. We also demonstrated that in bleomycin-treated mice, CHI3L1 expression was acutely and transiently decreased during the injury phase and returned toward and eventually exceeded baseline levels during the fibrotic phase. In this model, CHI3L1 played a protective role in injury by ameliorating inflammation and cell death, and a profibrotic role in the repair phase by augmenting alternative macrophage activation, fibroblast proliferation, and matrix deposition. Using three-dimensional culture system of a human fibroblast cell line, we found that CHI3L1 is sufficient to induce low grade myofibroblast transformation. In combination, these studies demonstrate that CHI3L1 is stimulated in IPF, where it represents an attempt to diminish injury and induce repair. They also demonstrate that high levels of CHI3L1 are associated with disease progression in ambulatory patients and that a failure of the CHI3L1 antiapoptotic response might contribute to preterminal disease exacerbations.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24920662      PMCID: PMC4340473          DOI: 10.1126/scitranslmed.3007096

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  61 in total

Review 1.  Mechanisms of pulmonary fibrosis.

Authors:  Victor J Thannickal; Galen B Toews; Eric S White; Joseph P Lynch; Fernando J Martinez
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.

Authors:  Lynne A Murray; Qingsheng Chen; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Xueyang Peng; Mridu Gulati; Robert J Homer; Thomas Russell; Nico van Rooijen; Jack A Elias; Cory M Hogaboam; Erica L Herzog
Journal:  Int J Biochem Cell Biol       Date:  2010-10-29       Impact factor: 5.085

3.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

4.  Fibroblast engraftment in the decellularized mouse lung occurs via a β1-integrin-dependent, FAK-dependent pathway that is mediated by ERK and opposed by AKT.

Authors:  Huanxing Sun; Elizabeth Calle; Xiaosong Chen; Aditi Mathur; Yangyang Zhu; Julio Mendez; Liping Zhao; Laura Niklason; Xueyan Peng; Hong Peng; Erica L Herzog
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-13       Impact factor: 5.464

Review 5.  Asbestosis and silicosis.

Authors:  G R Wagner
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

6.  Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP).

Authors:  J V Barbas-Filho; M A Ferreira; A Sesso; R A Kairalla; C R Carvalho; V L Capelozzi
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

7.  The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury.

Authors:  Myung Hyun Sohn; Min-Jong Kang; Hiroshi Matsuura; Vineet Bhandari; Ning-Yuan Chen; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Crit Care Med       Date:  2010-06-17       Impact factor: 21.405

8.  Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis.

Authors:  Ichiro Inoshima; Kazuyoshi Kuwano; Naoki Hamada; Michihiro Yoshimi; Takashige Maeyama; Naoki Hagimoto; Yoichi Nakanishi; Nobuyuki Hara
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-04       Impact factor: 5.464

9.  Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists.

Authors:  Bruce D Uhal; Rongqi Wang; Jeremy Laukka; Jiaju Zhuang; Valerie Soledad-Conrad; Gerasimos Filippatos
Journal:  Pharmacol Toxicol       Date:  2003-02

10.  Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.

Authors:  Yang Zhou; Jae-Young Lee; Chang-Min Lee; Won-Kyung Cho; Min-Jong Kang; Jonathan L Koff; Pyeong-Oh Yoon; Jeiwook Chae; Han-Oh Park; Jack A Elias; Chun Geun Lee
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

View more
  81 in total

1.  Characterization of Distinct Macrophage Subpopulations during Nitrogen Mustard-Induced Lung Injury and Fibrosis.

Authors:  Alessandro Venosa; Rama Malaviya; Hyejeong Choi; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Am J Respir Cell Mol Biol       Date:  2016-03       Impact factor: 6.914

2.  Landmark approvals in idiopathic pulmonary fibrosis.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-11       Impact factor: 54.908

3.  Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

Authors:  Yuliya Afinogenova; Jiapeng Ruan; Ruhua Yang; Nathaniel Kleytman; Gregory Pastores; Andrew Lischuk; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2019-07-23       Impact factor: 4.797

4.  Protective role of spleen-derived macrophages in lung inflammation, injury, and fibrosis induced by nitrogen mustard.

Authors:  Alessandro Venosa; Rama Malaviya; Andrew J Gow; Leroy Hall; Jeffrey D Laskin; Debra L Laskin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-16       Impact factor: 5.464

5.  Galectin-3 Interacts with the CHI3L1 Axis and Contributes to Hermansky-Pudlak Syndrome Lung Disease.

Authors:  Yang Zhou; Chuan Hua He; Daniel S Yang; Tung Nguyen; Yueming Cao; Suchitra Kamle; Chang-Min Lee; Bernadette R Gochuico; William A Gahl; Barry S Shea; Chun Geun Lee; Jack A Elias
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

Review 6.  Cell Death in the Lung: The Apoptosis-Necroptosis Axis.

Authors:  Maor Sauler; Isabel S Bazan; Patty J Lee
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

7.  GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease.

Authors:  Li Li; E Tian; Xianwei Chen; Jianfei Chao; Jeremy Klein; Qiuhao Qu; Guihua Sun; Guoqiang Sun; Yanzhou Huang; Charles D Warden; Peng Ye; Lizhao Feng; Xinqiang Li; Qi Cui; Abdullah Sultan; Panagiotis Douvaras; Valentina Fossati; Neville E Sanjana; Arthur D Riggs; Yanhong Shi
Journal:  Cell Stem Cell       Date:  2018-08-02       Impact factor: 24.633

8.  Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial.

Authors:  Chirag R Parikh; Caroline Liu; Maria K Mor; Paul M Palevsky; James S Kaufman; Heather Thiessen Philbrook; Steven D Weisbord
Journal:  Am J Kidney Dis       Date:  2019-09-20       Impact factor: 8.860

9.  Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis.

Authors:  Zhongwei Cao; Tinghong Ye; Yue Sun; Gaili Ji; Koji Shido; Yutian Chen; Lin Luo; Feifei Na; Xiaoyan Li; Zhen Huang; Jane L Ko; Vivek Mittal; Lina Qiao; Chong Chen; Fernando J Martinez; Shahin Rafii; Bi-Sen Ding
Journal:  Sci Transl Med       Date:  2017-08-30       Impact factor: 17.956

10.  YKL-40 Associates with Renal Recovery in Deceased Donor Kidney Transplantation.

Authors:  Jeremy Puthumana; Isaac E Hall; Peter P Reese; Bernd Schröppel; Francis L Weng; Heather Thiessen-Philbrook; Mona D Doshi; Veena Rao; Chun Geun Lee; Jack A Elias; Lloyd G Cantley; Chirag R Parikh
Journal:  J Am Soc Nephrol       Date:  2016-07-22       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.